Annual Report · 10-K
Insmed Incorporated
INSMNASDAQEQUITYCurrent
Annual Report
Company context
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines - including two approved therapies to treat chronic, debilitating lung diseases - as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗